TriNet Group (TNET) Q4 2025 earnings summary

Executive summary

• Delivered solid financial performance in a challenging SMB environment with high medical cost inflation and muted hiring activity, finishing at the top end of earnings guidance and generating 16% free cash flow growth.

• Improved pricing processes, completed comprehensive health fee renewal, and strengthened risk position for 2026.

• Investments in client service, go-to-market execution, and operational efficiency are driving momentum, with sales up in January and broker channel expansion underway.

• Achieved all-time high Net Promoter Score and will launch an AI-powered HR tool, TriNet Assistant, to enhance client experience.

• Exited 2025 with expenses down 7% year-over-year and expect further improvement in 2026.

Financial highlights

• Total revenues declined 2% year-over-year in Q4 and 1% for the full year, in line with guidance; Q4 revenues were $1.2 billion and full-year revenues $5.0 billion.

• Q4 net loss was $1 million ($(0.01) per share), improved from a $23 million loss last year; full-year net income was $155 million ($3.20 per diluted share), down from $173 million ($3.43 per share) in 2024.

• Adjusted earnings per diluted share was $0.46 in Q4 and $4.73 for the year, at the top end of guidance.

• Generated $425 million in adjusted EBITDA for 2025 (8.5% margin) and $234 million in free cash flow (16% growth year-over-year), with a free cash flow conversion ratio of 55%.

• Ended 2025 with 323,000 total WSEs, down 10% year-over-year; co-employed WSEs at 294,000, down 11%.

Outlook and guidance

• 2026 revenue guidance: $4.75B–$4.9B, reflecting lower starting WSE base and expected elevated Q1 attrition; professional service revenues $625–$645 million.

• Retention expected to improve slightly in 2026 as health fee increases moderate after January renewals.

• New sales growth anticipated throughout 2026, with ASO services expected to grow double digits.

• Insurance cost ratio guidance tightened to 90.75%-89.25%, reflecting improved actuarial capabilities.

• Adjusted EBITDA margin forecasted at 7.5%-8.7%; adjusted EPS guidance: $3.70–$4.70.